Cargando…

Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.

We established a panel of 17 xenografts from primary human breast carcinomas. We examined which characteristics of the original tumours and the xenografts facilitate growth in animals. Tumours expressing medium or strong immunoreactivity for p53 protein had significantly (P < 0.05) higher inciden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, R. R., Graves, J. M., Warso, M. A., Das Gupta, T. K.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1995
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033916/ https://www.ncbi.nlm.nih.gov/pubmed/7577462

Ejemplares similares

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice
por: Parris, Amanda B., et al.
Publicado: (2017)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

c-erbB-3 protein expression in ovarian tumours.
por: Simpson, B. J., et al.
Publicado: (1995)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.
por: Parkes, H. C., et al.
Publicado: (1990)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo
por: Lahlou, Hicham, et al.
Publicado: (2012)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D
por: Yang, Lu, et al.
Publicado: (2016)

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
por: Niskanen, E., et al.
Publicado: (1997)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

ErbB2 Dephosphorylation and Anti-Proliferative Effects of Neuregulin-1 in ErbB2-Overexpressing Cells; Re-evaluation of Their Low-Affinity Interaction
por: Wang, Ran, et al.
Publicado: (2013)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3
por: Young, Christian D, et al.
Publicado: (2008)

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
por: Houston, S J, et al.
Publicado: (1999)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Differences in the Binding Affinities of ErbB Family: Heterogeneity in the Prediction of Resistance Mutants
por: Pereira, Mariana, et al.
Publicado: (2013)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.
por: Lemoine, N. R., et al.
Publicado: (1991)

Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas
por: Gulati, Sasha, et al.
Publicado: (2010)

p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
por: Poller, D. N., et al.
Publicado: (1992)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

p53 and erbB-2 Are Not Associated in Matched Cases of Primary and Metastatic Ovarian Carcinomas
por: Rodríguez-Burford, Cristina, et al.
Publicado: (2003)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli, Meysam, et al.
Publicado: (2019)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

C-erbB-2 overexpression in primary breast cancer: relationship to clinical and histopathological parameters of patients with breast cancer
por: Regele, S, et al.
Publicado: (2001)

Expression of c-erbB3 protein in primary breast carcinomas.
por: Naidu, R., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_1eel04v641152s4re7koc5sqab